MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

Abstract Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phas...

Full description

Bibliographic Details
Main Authors: Antonio Uccelli, Alice Laroni, Lou Brundin, Michel Clanet, Oscar Fernandez, Seyed Massood Nabavi, Paolo A. Muraro, Roberto S. Oliveri, Ernst W. Radue, Johann Sellner, Per Soelberg Sorensen, Maria Pia Sormani, Jens Thomas Wuerfel, Mario A. Battaglia, Mark S. Freedman, on behalf of the MESEMS study group
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Trials
Subjects:
Multiple sclerosis
Mesenchymal stem cells
Mesenchymal stromal cells
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s13063-019-3346-z

Internet

http://link.springer.com/article/10.1186/s13063-019-3346-z

Similar Items